Page last updated: 2024-11-13

da 8159

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

udenafil: a pyrazolo-pyrimidinone similar to sildenafil; phosphodiesterase type 5 inhibitor; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135413547
CHEMBL ID2103849
CHEBI ID135926
SCHEMBL ID120993
MeSH IDM0378233

Synonyms (55)

Synonym
udenafil
zydena
da-8159
me-3113
benzenesulfonamide, 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-n-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxy-
5-(2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo(4,3-d)pyrimidine-7-one
CHEBI:135926
DB06267
3-(1-methyl-7-oxo-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
268203-93-6
da 8159
udenafil (usan/inn)
D10027
udenafil [usan:inn]
l5ib4xly36 ,
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-n-{2-((2rs)- 1-methylpyrrolidin-2-yl)ethyl}-4-propoxybenzenesulfonamide
unii-l5ib4xly36
CHEMBL2103849
FT-0675724
AKOS015902221
S6433
3-(1-methyl-7-oxo-3-propoxy-4,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-n-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide
udenafil [mart.]
3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-n-(2-((2rs)- 1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide
udenafil [inn]
udenafil [mi]
benzenesulfonamide, 3-(4,7-dihydro-1-methyl-7-oxo-3-propoxy-1h-pyrazolo(4,3-d)pyrimidin-5-yl)-n-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxy-
udenafil [who-dd]
udenafil [usan]
HY-18253
SCHEMBL120993
IYFNEFQTYQPVOC-UHFFFAOYSA-N
3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-4-propoxy-benzenesulfonamide
3-{1-methyl-7-oxo-3-propyl-1h,4h,7h-pyrazolo[4,3-d]pyrimidin-5-yl}-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide
J-016558
5-[2-propyloxy-5-[2-(1-methyl-2-pyrrolidinyl)ethylaminosulfonyl]phenyl]-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo[4,3-d]pyrimidine-7-one
EX-A3836
FT-0675725
da8159;da 8159;da-8159;zydena
BCP07585
Q4815980
BS-16833
SB17350
da8159da8159
cid 6918523
D70636
gtpl11577
3-(1-methyl-7-oxo-3-propyl-6h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
A898349
3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide
benzenesulfonamide, 3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxy-; benzenesulfonamide, 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-n-[2-(1-methyl-2-pyr
DTXSID00870301
Z2235811577
bdbm50602175
AKOS040742801

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Any adverse events were also recorded during the trial."( The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.
Ahn, TY; Choi, HK; Kim, JJ; Kim, SC; Kim, SW; Lee, SW; Paick, JS; Suh, JK; Yang, DY, 2008
)
0.35
" Treatment-related adverse events were generally mild to moderate with facial flushing and headache being the most common."( The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.
Ahn, TY; Choi, HK; Kim, JJ; Kim, SC; Kim, SW; Lee, SW; Paick, JS; Suh, JK; Yang, DY, 2008
)
0.35
" Udenafil was safe and well tolerated in healthy Korean subjects."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
" Safety and tolerability were evaluated by monitoring clinical laboratory parameters and adverse events."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
" Udenafil was generally well tolerated in these healthy subjects, and no serious adverse events occurred."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
"Udenafil was safe and well tolerated in healthy volunteers."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
" The coadministration of udenafil and an alpha-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED."( Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
Chung, BH; Lee, JY; Lee, SH; Lee, SW; Oh, CY; Yoo, SJ,
)
0.13
" Headache and flushing were the most common treatment-emergent adverse events, which were transient and mild-to-moderate in nature."( The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents.
Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Moon, KH; Paick, JS; Park, K; Park, NC; Park, YK, 2009
)
0.35
" The treatment did not increase the frequency or severity of adverse events."( The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents.
Chung, WS; Hyun, JS; Kim, SW; Lee, SW; Moon, KH; Paick, JS; Park, K; Park, NC; Park, YK, 2009
)
0.35
" Flushing was the most common treatment-related adverse event, which was transient and mild to moderate in severity."( Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Ahn, TY; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Paick, JS; Park, JK; Park, K; Park, NC; Yang, DY; Zhao, C, 2011
)
0.37
" The incidence of adverse events was relatively low and well tolerated in patients with DM."( A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus.
Ahn, TY; Kim, JJ; Lee, CH; Min, KS; Moon, du G; Park, JK; Park, K; Yang, DY, 2011
)
0.37
" The outcome measures assessed were the change from baseline for the International Index of Erectile Function erectile function domain score (primary), the change from baseline for Sexual Encounter Profile questions 2 and 3, the shift to normal rate (erectile function domain ≥ 26), the response to the Global Assessment Questionnaire and adverse effects (secondary)."( Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials.
Ding, H; Du, C; Du, W; Tao, Y; Wang, H; Wang, Z; Zhang, L, 2012
)
0.38
" All included studies indicated that most adverse events were mild or moderate in severity, and no serious adverse events were reported during the study period."( Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials.
Ding, H; Du, C; Du, W; Tao, Y; Wang, H; Wang, Z; Zhang, L, 2012
)
0.38
" Daily udenafil was well-tolerated, and there was no significant difference in the adverse drug reactions and adverse events between the two groups."( Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction.
Cha, BY; Kim, TH; Lee, JM; Min, KW; Park, IeB; Park, KS; Park, SH; Park, SW; Sung, YA,
)
0.13
" Treatment-related adverse events (n = 4) were all mild in severity."( Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial.
Choi, GS; Choi, JI; Kim, HJ; Park, JA; Park, JS; Park, SY, 2015
)
0.42
"Oral udenafil was deemed safe and effective for the treatment of erectile dysfunction in patients who underwent TME for rectal cancer."( Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: a randomized, double-blind, placebo-controlled trial.
Choi, GS; Choi, JI; Kim, HJ; Park, JA; Park, JS; Park, SY, 2015
)
0.42
"Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated."( A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
Ahn, TY; Chung, WS; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Moon, du G; Moon, KH; Paick, JS; Park, JK; Park, K; Park, NC; Shin, HS; Yang, DY, 2016
)
0.43
" The occurrence rate of adverse drug reactions was 8%, which consisted mainly of flushing and headache."( A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
Ahn, TY; Chung, WS; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Moon, du G; Moon, KH; Paick, JS; Park, JK; Park, K; Park, NC; Shin, HS; Yang, DY, 2016
)
0.43
" The safety profile and adverse effects of udenafil were similar to those of typical phosphodiesterase-5 inhibitors seen in previous studies."( Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Chang, HJ; Chang, SA; Choi, JH; Jeong, JO; Jung, HO; Kim, DK; Kim, HK; Kim, KH; Lee, JH; Lee, JS; Song, S, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic parameters of DA-8159, a new erectogenic, were compared after intravenous and oral administration of the drug at a dose of 30 mg/kg to control rats and rats with acute renal failure induced by uranyl nitrate (U-ARF)."( Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate.
Kim, DG; Kim, EJ; Kim, WB; Kim, YC; Kwon, JW; Lee, MG; Shim, HJ, 2004
)
0.32
" Our results indicated that the DA-8159 data obtained from four laboratory animals could be utilized to generate preliminary estimates of the pharmacokinetic parameters in humans."( Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Kim, SH; Kim, WB; Kim, YC; Kim, YG; Kwon, JW; Lee, JH; Lee, MG; Shim, HJ, 2005
)
0.33
" After oral administration of DA-8159 at a dose of 30 mg/kg to rats without or with cola beverage, the pharmacokinetic parameters of DA-8159 and DA-8164 were not significantly different between two groups of rats."( Effects of omeprazole or cola beverage on the pharmacokinetics of oral DA-8159, a new erectogenic, in rats.
Bae, SK; Kim, WB; Kwon, JW; Lee, JH; Lee, MG, 2005
)
0.33
"The pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d)pyrimidine-7-one (DA-8159), a new erectogenic, and nitroglycerin has been evaluated in rats."( Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats.
Bae, SK; Kwon, JW; Lee, DC; Lee, MG; Lee, SJ; You, M, 2005
)
0.33
"A pharmacokinetic interaction between oral DA-8159 and amlodipine was evaluated in male Sprague-Dawley rats."( Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats.
Kim, EJ; Kwon, JW; Lee, JH; Lee, MG; Yoo, M, 2006
)
0.33
" Therefore, this study was performed with DA-8159 (a long acting PDE 5 inhibitor) and terazosin in rats to find whether or not pharmacokinetic and pharmacodynamic interactions between the two drugs were observed."( Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.
Bae, SK; Kwon, JW; Lee, DC; Lee, MG; Oh, EY; You, M, 2007
)
0.34
" Therefore, in this study we investigated whether a pharmacokinetic interaction occurs between DA-8159 and metformin, as both drugs are metabolized via hepatic CYP3A1/2 in rats."( Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2.
Choi, YH; Chung, SJ; Lee, MG, 2008
)
0.35
" After intravenous and oral administration of DA-8159, most of the pharmacokinetic parameters of DA-8159 and DA-8164 were not significantly different between two groups of rats."( Effects of bacterial lipopolysaccharide on the pharmacokinetics of DA-8159, a new erectogenic, in rats.
Kim, WB; Kim, YC; Kwon, JW; Lee, JH; Lee, MG, 2005
)
0.33
" This method was successfully applied for pharmacokinetic study after oral administration of udenafil 100 mg to healthy Korean male volunteers."( Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Bae, SK; Kang, MJ; Kim, MJ; Liu, KH; Shin, JG; Shon, JH; Yeo, CW, 2008
)
0.35
" The median time to reach the C(max) was delayed in the co-administrated treatment, while the mean terminal elimination half-life (t(1/2)) remained relatively unchanged regardless of ketoconazole co-administration."( Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
Cho, JY; Chung, YJ; Jang, IJ; Kim, BH; Kim, HS; Kim, TE; Shin, KH; Shin, SG; Yu, KS, 2010
)
0.36
" This chromatographic procedure was then applied to the in vivo pharmacokinetic studies in rats for determining the advantages of intranasal administration of the drug over oral administration."( Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats.
Cha, BJ; Cho, HJ; Chung, SJ; Kang, SK; Kim, DD; Kim, JH; Kim, JS; Kim, KM; Ku, WS; Shim, CK; Yoon, IS, 2011
)
0.37
" The aim of the study reported here was to investigate the pharmacokinetic drug interaction between udenafil and dapoxetine in healthy male subjects."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.42
" Pharmacokinetic parameters were obtained by non-compartmental analysis."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.42
"Udenafil was found to have no clinically significant pharmacokinetic interactions with dapoxetine."( Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Bae, KS; Bahng, MY; Choi, HY; Jeon, HS; Kim, YH; Lee, SH; Lim, HS, 2015
)
0.42
"The aim of this study was to develop a population pharmacokinetic (PK) model of udenafil and its active metabolite, DA-8164, in healthy subjects and patients with hepatic impairment (HI) and to estimate the optimal dosing recommendations for patients with HI."( Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.
Bahng, MY; Cho, JY; Jang, IJ; Jung, YJ; Kim, A; Lee, J; Shin, D, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"Perform a systematic review and meta-analysis of available prospective and cross-sectional studies on the use of PDE5-Is alone or in combination with α1-adrenergic blockers in patients with LUTS/benign prostatic hyperplasia (BPH)."( A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Carini, M; Corona, G; Gacci, M; Kaplan, SA; Maggi, M; McVary, KT; Mirone, V; Roehrborn, CG; Salvi, M; Serni, S; Vignozzi, L, 2012
)
0.38
"We evaluated the effect of chronic administration of PDE5 combined with glycemic control on DMED."( Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats.
Cho, SY; Choi, WS; Kim, SW; Kwon, OS; Paick, JS, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" The extent of absolute oral bioavailability (F) of DA-8159 was 38."( Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Kim, DS; Kim, WB; Kim, YC; Kwon, JW; Lee, MG; Park, KJ; Shim, HJ, 2003
)
0.32
" However, although the C(max) was reduced by approximately 21% in the low fat-fed state, overall bioavailability was not affected when taken with food."( Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction.
Hong, JH; Jang, IJ; Kim, BH; Kim, HS; Kim, JR; Kim, KP; Kim, TE; Lim, KS; Shin, SG; Yu, KS, 2009
)
0.35
"To achieve rapid onset of action and improved bioavailability of udenafil, a microemulsion system was developed for its intranasal delivery."( Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations.
Cho, HJ; Chung, CW; Kim, DD; Ku, WS; Moon, HT; Termsarasab, U; Yoon, I, 2012
)
0.38
" Previous studies suggested that decreased NO bioavailability may result in the downregulation of klotho expression, but the relationship between klotho and NO remains obscure."( The mechanism of attenuation of epithelial-mesenchymal transition by a phosphodiesterase 5 inhibitor via renal klotho expression.
Choi, SO; Han, BG; Han, ST; Kim, JS; Kim, MK; Lee, JY; Yang, JW; Yoo, JS, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The subjects were allocated to single-dose groups of 25, 50, 100, 200 or 300 mg (eight subjects in each dose group, including two placebos), or to multiple-dose groups of 100 or 200 mg (once-daily dosing for 7 days; nine subjects in each dose group, including three placebos)."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
" During multiple dosing, a steady state was reached at 5 days and little accumulation occurred after repeated dosing for 7 days."( Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
Cho, JY; Chung, JY; Jang, IJ; Kim, BH; Kim, JR; Lim, HS; Lim, KS; Paick, JS; Shin, SG; Sohn, DR; Yu, KS, 2008
)
0.35
" The inhibition was also observed in human liver S9 fractions, suggesting that a reassessment of the oral dosage of tamsulosin is necessary when udenafil and tamsulosin are co-administered to patients with benign prostatic hyperplasia."( Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2.
Bae, SK; Kang, HE; Kim, YG; Lee, DC; Lee, MG; Yoo, M, 2009
)
0.35
" When the contraction was stabilized, a dose-response curve of udenafil was constructed."( Relaxation effect of phosphodiesterase-5 inhibitor on the animal bladder and prostatic urethra: in vitro and in vivo study.
Bae, JH; Cho, DY; Kang, SH; Lee, JG; Moon, du G; Park, HS, 2010
)
0.36
" On day 3 of ketoconazole treatment, a second 100 mg of udenafil was dosed concomitantly."( Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
Cho, JY; Chung, YJ; Jang, IJ; Kim, BH; Kim, HS; Kim, TE; Shin, KH; Shin, SG; Yu, KS, 2010
)
0.36
"19 when udenafil was dosed in the presence of ketoconazole."( Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.
Cho, JY; Chung, YJ; Jang, IJ; Kim, BH; Kim, HS; Kim, TE; Shin, KH; Shin, SG; Yu, KS, 2010
)
0.36
" Participants were requested to attempt sexual intercourse at 12 hours after udenafil or placebo dosing during a 4-week treatment period."( Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.
Min, K; Park, HJ; Park, JK; Park, K; Park, NC, 2010
)
0.36
"This study was performed to investigate the effect of repeated dosing of udenafil, a novel phosphodiesterase type 5 inhibitor, on penile hypoxia and fibrosis induced by bilateral cavernous nerve resection (BCNR) in rats."( Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection.
Ahn, BO; Ahn, GJ; Kang, KK; Lee, CH; Shin, JH; Yoo, M, 2010
)
0.36
"While fibrosis, apoptosis, and the expression of TGF-beta1, HIF-1 alpha, and ET(B) were significantly increased, and the expression of eNOS and nNOS were significantly decreased in group II, compared with the sham-operated animals, repeated dosing of udenafil significantly ameliorated these changes."( Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection.
Ahn, BO; Ahn, GJ; Kang, KK; Lee, CH; Shin, JH; Yoo, M, 2010
)
0.36
" This study also suggests the potential beneficial role of repeated dosing of udenafil in the recovery of erectile function in patients with neuronal erectile dysfunction."( Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection.
Ahn, BO; Ahn, GJ; Kang, KK; Lee, CH; Shin, JH; Yoo, M, 2010
)
0.36
"  This study was designed to investigate whether repeated dosing of udenafil, a phosphodiesterase type 5 inhibitor, helps to improve erectile function after CN injury."( Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury.
Ahn, BO; Goo, MJ; Kang, KK; Kim, HS; Kim, SH; Lee, CH; Yang, DY, 2011
)
0.37
"A once-daily dosing regimen with a phosphodiesterase type 5 inhibitor is needed for the treatment of erectile dysfunction (ED), in part because of the behavioral complexities associated with sexual intimacy."( Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Ahn, TY; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Paick, JS; Park, JK; Park, K; Park, NC; Yang, DY; Zhao, C, 2011
)
0.37
"To evaluate the efficacy and safety of once-daily dosing of udenafil in the treatment of ED."( Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Ahn, TY; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Paick, JS; Park, JK; Park, K; Park, NC; Yang, DY; Zhao, C, 2011
)
0.37
" To investigate the efficacy of repeated dosing with a PDE5 inhibitor on cognitive function and somatization in patients with erectile dysfunction, 27 patients with erectile dysfunction received udenafil (100 mg) at 3-day intervals for 2 months."( Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study.
Kim, HW; Kim, JC; Kim, SW; Koh, JS; Pae, CU; Shim, YS,
)
0.13
" There is level 5 evidence (expert opinion) that combination therapy of PDE5 inhibitors + L-arginine or daily dosing of tadalafil + short-acting PDE5 inhibitors pro re nata may rescue PDE5 inhibitor monotherapy failures."( SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Brock, G; Burnett, A; Ghanem, H; Giuliano, F; Glina, S; Hellstrom, W; Martin-Morales, A; Porst, H; Salonia, A; Sharlip, I, 2013
)
0.39
" Daily dosing with a PDE5 inhibitor seems to improve cognitive function, depression and somatization, as well as erectile function, in patients with ED."( Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.
Cho, KJ; Kim, JC; Kim, SW; Koh, JS; Pae, CU; Shim, YS,
)
0.13
"We compared the efficacy and safety between once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction (ED)."( Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction.
Cha, BY; Kim, TH; Lee, JM; Min, KW; Park, IeB; Park, KS; Park, SH; Park, SW; Sung, YA,
)
0.13
" After 10 weeks of induced diabetes, the DM-I group was treated with a daily injection of neutral protamine Hagedorn, and the DM-P group was treated with a daily dosage of 20 mg/kg PDE5 (DA-8159) for 4 weeks."( Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats.
Cho, SY; Choi, WS; Kim, SW; Kwon, OS; Paick, JS, 2015
)
0.42
" Pharmacokinetics were measured in the two lowest dosage groups."( The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.
Appenrodt, B; Caca, K; Deibert, P; Dilger, K; Ferlitsch, A; Greinwald, R; Kreisel, W; Kupcinskas, L; Mohrbacher, R; Neagu, M; Rössle, M; Roth, S; Sauerbruch, T; Sumskiene, J; Zipprich, A, 2015
)
0.42
"The method of administration of oral phosphodiesterase-5 inhibitors has been expanded to once-daily repeated administration with lower initial dosage than on-demand administration."( Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial.
Ahn, TY; Chung, WS; Kim, JJ; Kim, SW; Ko, YH; Lee, SW; Min, KS; Moon, du G; Moon, KH; Paick, JS; Park, JK; Park, K; Park, NC; Yang, DY, 2015
)
0.42
"The aim of this study was to develop a population pharmacokinetic (PK) model of udenafil and its active metabolite, DA-8164, in healthy subjects and patients with hepatic impairment (HI) and to estimate the optimal dosing recommendations for patients with HI."( Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.
Bahng, MY; Cho, JY; Jang, IJ; Jung, YJ; Kim, A; Lee, J; Shin, D, 2016
)
0.43
"Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life."( A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction.
Ahn, TY; Chung, WS; Kim, JJ; Kim, SW; Lee, SW; Min, KS; Moon, du G; Moon, KH; Paick, JS; Park, JK; Park, K; Park, NC; Shin, HS; Yang, DY, 2016
)
0.43
"5 mg bid cohort was well tolerated, achieved the highest maximal concentration (506 ng/mL) and the highest average concentration over the dosing interval (279 ng/mL), and was associated with a suggestion of improvement in myocardial performance."( Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.
Chen, S; deVries, TM; Goldberg, DJ; Goldstein, BH; Hamstra, MS; Kaltman, JR; Maunsell, E; Menon, SC; Mital, S; Paridon, SM; Payne, RM; Radojewski, EA; Schumacher, KR; Stylianou, M; Yeager, JL; Zak, V, 2017
)
0.46
"Udenafil was well-tolerated at all dosing levels."( Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.
Chen, S; deVries, TM; Goldberg, DJ; Goldstein, BH; Hamstra, MS; Kaltman, JR; Maunsell, E; Menon, SC; Mital, S; Paridon, SM; Payne, RM; Radojewski, EA; Schumacher, KR; Stylianou, M; Yeager, JL; Zak, V, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)0.00820.00001.18439.6140AID1897138
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1897138Inhibition of PDE5 (unknown origin)2022RSC medicinal chemistry, Nov-16, Volume: 13, Issue:11
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's51 (44.35)29.6817
2010's55 (47.83)24.3611
2020's9 (7.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (26.32%)5.53%
Reviews11 (8.27%)6.00%
Case Studies2 (1.50%)4.05%
Observational0 (0.00%)0.25%
Other85 (63.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]